English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Sirona Announces Positive Preclinical Toxicology Results for its SGLT2 Inhibitor in China

Mar. 4, 2015

On March 4, 2015, Sirona Biochem Corp. announced that Wanbang Biopharmaceuticals has successfully completed the toxicology study in the pre-clinical validation of its anti-diabetic SGLT2 Inhibitor SBM-TFC-039 for the treatment of Type 2 diabetes.

The results of the study demonstrated that the maximum tolerated dose (MTD) of SBM-TFC-039 was greater than 800 mg/kg/day, which was significantly greater than the 300 mg/kg/day of the Canagliflozin reference. There was no mortality in the groups treated with SBM-TFC-039 and the histopathology showed no visual abnormalities.

The reference drug Canagliflozin is Johnson and Johnson’s SGLT2 inhibitor for type 2 diabetes. It was the first SGLT2 inhibitor launched and it has been on the market in many countries, including the United States, since 2013.